Characterization of the Dexniguldipine Binding Site in the Multidrug Resistance-Related Transport Protein P-Glycoprotein by Photoaffinity Labeling and Mass Spectrometry

CHRISTOPH BORCHERS,1 RAINER BOER, KURT KLEMM, VOLKER FIGALA, THOMAS DENZINGER, WOLF-RÜDIGER ULRICH, SABINE HAAS, WOLFGANG ISE, VOLKER GEKELER, and MICHAEL PRZYBYLSKI


Received January 15, 2002; accepted January 25, 2002 This article is available online at http://molpharm.aspetjournals.org

ABSTRACT

Human P-glycoprotein (P-gp), an integral membrane transport protein, is responsible for the efflux of various drugs, including cytostatics from cancer cells leading to multidrug resistance. P-gp is composed of two homologous half domains, each carrying one nucleotide binding site. The drug extrusion is ATP-dependent and can be inhibited by chemosensitizers, such as the dihydropyridine derivative dexniguldipine-HCl, through direct interaction with P-gp. To evaluate the mechanism(s) of chemosensitization and identify the binding sites of dexniguldipine-HCl, a tritium-labeled azido analog of dexniguldipine, [3H]B9209-005, was used as a photoaffinity probe. Using the multidrug resistant T-lymphoblastoid cell line CCRF-ADR5000, two proteins were specifically labeled in membranes by [3H]B9209-005. These proteins were identified by immunoprecipitation such as P-gp and its N-terminal fragment. The membranes were solubilized and the labeled P-gp proteins first isolated by lectin-chromatography and then digested with trypsin. SDS-polyacrylamide gel electrophoresis analysis of the digest revealed a major radioactive 7-kDa fragment. The tryptic fragments were separated by high-performance liquid chromatography and analyzed by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). The MS results, corroborated by MALDI-MS of peptides after one step of Edman analysis, identified the radioactive 7-kDa band as the dexniguldipine-bound, tryptic P-gp peptide, 468–527. This sequence region is flanked by the Walker motifs A and B of the N-terminal ATP-binding cassette suggesting direct interaction of the chemosensitizer with the nucleotide binding site is involved in the mechanism of chemosensitization.

Tumor cells in vitro and in vivo can develop simultaneous resistance to the lethal effects of a variety of cytotoxic drugs (Endicott and Ling, 1989). This so-called multidrug resistance (MDR) is a major limiting factor for the efficacy of cancer chemotherapy. Currently, a variety of mechanisms are known that can lead to drug resistance, including reduced cellular drug accumulation, increased detoxification, intracellular vesicularization of drugs, altered enzymatic activities, up- or down-regulation of targets, and enhanced DNA repair (Hayes and Wolf, 1990). One important resistance mechanism is the transport out of cancer cells of chemically-unrelated cytotoxic drugs (such as anthracyclines, Vinca alkaloids, colchicine, and taxanes) by the integral membrane phosphoglycoprotein P-glycoprotein (P-gp) under ATP hydrolysis, resulting in low and ineffective intracellular drug concentrations (Gottesman and Pastan, 1993). Although considerable progress has been made during the last few years, the mechanism of recognition and transport of such a broad spectrum of compounds is still poorly understood.

Reversal of multidrug resistance is of major clinical interest, and MDR-reversing agents called chemosensitizers have been intensively investigated (Raderer and Scheithauer, 1993; Sikic, 1993). The capability of reversing multidrug resistance in vitro by inhibiting the transport function of P-gp has been demonstrated for a number of compounds. One

ABBREVIATIONS: MDR, multidrug resistance; P-gp, P-glycoprotein; SDZ PSC 833, [3-keto-Bmt1]-[Val2]-cyclosporin; NBD, nucleotide-binding domain; [3H]B9209-005, 3-[3-(4-[3H]phenyl-4-phenyl-1-piperidinyl)propyl]-5-methyl-4(R)-3-azidophenyl]-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate; deoxy-BIGCHAP, N,N′-bis-(3-o-gluconamidopropyl)deoxycholic acid; PAGE, polyacrylamide gel electrophoresis; TBS, Tris-buffered saline; TBS/T, Tris-buffered saline containing 0.05% Tween 20; PITC, phenyl isothiocyanate; TFA, trifluoroacetic acid; HPLC, high-performance liquid chromatography; MALDI, matrix-assisted laser desorption/ionization; aa, amino acids.
of the best characterized agents is verapamil, whose first clinical trial was reported in 1984 (Present et al., 1984). Other compounds with MDR-reversing activity are cyclosporin A (Raderer and Scheithauer, 1993), SDZ PSC 833 (Fisher et al., 1994), and the 1,4-dihydropyridine derivative dexniguldipine-HCl (Reiter et al., 1994).

Human P-gp has an apparent molecular mass of 170 kDa and consists of 1280 amino acids encompassing two homologous halves (Chen et al., 1986). A short linker region connects the two domains and each half contains a nucleotide-binding domain (NBD) with "homology A" and "homology B" sequences commonly found in ATPases. Both ATP binding sites are catalytically active and are essential for drug extrusion (Azzaria et al., 1989; Urbatsch et al., 1995). A structural model of P-gp, derived from hydropathy plots, has been suggested to comprise six transmembrane-spanning α-helical segments, followed by a cytoplasmic NBD for each half of the molecule (Gottesman and Pastan, 1988; Juranka et al., 1989).

A recent model has proposed two membrane-embedded sixteen-strand β-barrels, connected by short loops to two six-helix bundles beneath each barrel (Jones and George, 1998) (Fig. 7). A first insight into the three-dimensional architecture of P-gp was recently obtained by electron microscopy (Rosenberg et al., 1997) and structure determination at 2.5-nm low resolution, which, however, did not provide sufficient information for the understanding of the molecular transport mechanism.

Because drug binding must precede transport, the determination of the structural area involved in the binding is essential for elucidation of a structure-function relationship. Furthermore, the localization of the chemosensitization binding site can provide information on how this site is interacting with the drug binding and how the NBD is linked to drug transport and inhibition. To determine the binding area, domain mapping studies using photoaffinity analogs of drugs or chemosensitizers have been used in combination with immunoprecipitation (Safa, 1998). Detailed studies have been performed with a photoactive 1,4-dihydropyridine derivative, [3H]azidopine, and with [125I]iodoarylazidoprazosin (Greenberger, 1998) and have located two major regions of photoaffinity labeling, one within each half of the protein (Bruggemann et al., 1989; Greenberger et al., 1991; Morris et al., 1994).

In this study, we used a tritiated photoaffinity derivative of the chemosensitizer dexniguldipine-HCl ([3H]B9209-005) to probe the dihydropyridine binding site in P-gp. To obtain the photoreactive dexniguldipine derivative, an azido group replaced the nitro group in position 3 of the phenyl ring in the 4-phenyldihydropyridine moiety. As demonstrated earlier, this structural modification does not affect the chemosensitizing potency of the molecule (Borchers et al., 1995; Boer et al., 1996). Although the two dihydropyridine derivatives, B9209-005 and azidopine, are related molecules, the photoreactive groups are in different positions, with azidopine carrying the azido group in the side chain of the dihydropyridine moiety. Compared with azidopine, B9209-005 has been shown to be a ~10-fold more potent chemosensitizer (Borchers et al., 1995) and, hence, seemed to be a suitable ligand for the elucidation of the chemosensitizer binding sites.

It has been shown previously, that [3H]B9209-005 is specifically photoincorporated into P-gp and its N-terminal fragment (Borchers et al., 1995; Boer et al., 1996). To identify the binding site of dexniguldipine-HCl, we used a mass spectrometric approach instead of conventional immunoprecipitation with sequence-specific antibodies. In contrast to immunoprecipitation, mass spectrometry is, in general, not sequence-dependent, and even hydrophobic peptides, such as transmembrane domains, can be identified.

In the present study, we have used the combination of photoaffinity labeling and mass spectrometric peptide mapping (Przybylski et al., 1998) to localize the binding site of dexniguldipine-HCl. The results obtained are compared with those from azidopine and other photolabels and the location of the dihydropyridine binding site is discussed with respect to the two topological models of P-gp.

Experimental Procedures

Materials

Chemicals, Proteins, and Supplies. Dexniguldipine-HCl and [3H]B9209-005 were synthesized as described previously (Boer et al., 1996; Borchers et al., 1996). A specific radioactivity of 414 GBq/nmol (11.3 Ci/mmol) for [3H]B9209-005 was obtained. [3H]Azidopine was obtained from Amersham Biosciences (Braunschweig, Germany). The detergents CHAPS, deoxy-BIGCHAP, n-octylglucoside, deoxycholate, and Triton X-100 were purchased from Roche Applied Science (Mannheim, Germany), N-lauroylsarcosine and Nonidet P-40 were from Fluka (Buchs, Switzerland) and Zwittergent 3-12 was from Calbiochem (Bad Soden, Germany). Nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate were from Serva (Heidelberg, Germany). Tween 20, phenylsulfonyl fluoride, and o-cyano-4-hydroxycinnamic acid were purchased from Aldrich (Deisendorf, Germany).

Horse heart cytochrome C was from Fluka; bovine serum albumin, trypsin, and Rickettsia communis agglutinin-120 (RCA-120) immobilized on agarose beads were obtained from Sigma (Deisendorf, Germany).

Cell Lines and Antibodies. The human T-lymphoblastoid cell line CCRF-CEM was obtained from the American Type Culture Collection (Manassas, VA). The selection of the multidrug-resistant CCRF-ADR5000 subcell line has been reported previously (Kimmel et al., 1990). The cell lines were maintained as described previously (Borchers et al., 1995; Hofmann et al., 1995). The monoclonal antibody B219 was purchased from Centocor (Malvern, PA). Goat antimouse IgG and goat anti-rabbit IgG conjugated to alkaline phosphatase were purchased from Dianova (Hamburg, Germany). The production and purification of the polyclonal antibody 909 raised against a synthetic peptide corresponding to the P-gp amino acid sequence 909–927 was performed as described previously (Borchers et al., 1995).

Methods

Membrane Preparation and Photoaffinity Labeling. Plasma membrane preparation of CCRF-CEM and CCRF-ADR5000 cells and photoaffinity labeling with [3H]B9209-005 and [3H]azidopine have been reported in detail elsewhere (Borchers et al., 1995; Boer et al., 1996). Briefly, cells were homogenized in lysis buffer (10 mM NaCl, 1.5 mM MgCl₂, 10 mM Tris-HCl, pH 7.4) and membrane proteins were separated from cell nucleus and mitochondrial proteins by differential centrifugation. The resulting membrane pellet was resuspended in lysis buffer containing 50% glycerol. Protein concentration was determined by a bicinchoninic acid assay (Pierce, Rockford, IL) using bovine serum albumin as standard. For photoaffinity labeling, membranes (0.6 mg/ml) were incubated in PBS buffer, pH 7.4, in the presence of the photolabel for 1 h at 22°C in the dark. Irradiation was performed with a long-wave UV-lamp (Camag, Berlin, Germany) for 20 min at 4°C.

SDS-PAGE and Liquid Scintillation Counting. Gel electrophoretic analyses were performed according to the procedure of
laemmli with a 8% polyacrylamide SDS-gel for separation of proteins and a 7.5 to 20% polyacrylamide gradient SDS-gel for separation of proteolytic fragments. The samples were diluted 1:1 in sample buffer (0.25 M Tris-HCl, 5% mercaptoethanol, 2% SDS, 0.01% bromphenol blue, 50% glycerol, pH 6.8) and applied to gels after incubation for 30 min at 22°C. Gels were stained with 0.25% Coomassie G250 in 25% isopropanol/10% acetic acid overnight and destained with 10% acetic acid. For radioactivity determination, gels were cut into 1-mm slices and incubated with Biolute-S (Zinsser, Frankfurt, Germany) for 3 h at 50°C. Radioactivity was quantified by liquid scintillation counting.

Solubilization and Detergent Exchange. To determine the P-gp solubilization efficiency by detergents, CCRF-ADR5000 membranes (0.6 μg/μl) were photothalebated with 1.6 μM [3H]azidopine and homogenized with detergent solution (6% in 20 mM Tris-HCl, pH 7.4) at a final detergent concentration of 1% in a glass/glass homogenizer for 3 min at 4°C. After a 30-min incubation at 4°C, nonsolubilized proteins were removed by centrifugation (45,000 rpm; Optima TLX ultracentrifuge, rotor TLA-100.4, Beckmann, Karlsruhe, Germany) at 100,000g, 4°C. The supernatant was analyzed by SDS-PAGE. Solubilization with N-lauroylsarcosine was performed in the same manner. For purification of P-gp by RCA-120 chromatography, solubilization was carried out with 20 mM N-lauroylsarcosine in 20 mM Tris-HCl, pH 7.4.

Detergent exchange of P-gp solutions was performed by ultrafiltration using 500-μl Microcon centrifugal filter devices with a molecular mass cut-off of 100 kDa (Amicon, Eschborn, Germany). Ultrafiltration was carried out at 3000g and 22°C for 40 min with an Eppendorf centrifuge (Centrifuge 5415 C; Eppendorf, Germany) according to the manufacturer's instructions. After the first centrifugation, the Microcon centrifugal filter device was filled with 500 μl of detergent solution and centrifuged again for detergent exchange. This procedure was repeated four times.

Western Immunoblot Analysis. The membrane proteins were transferred onto Immobilon-P membranes (Millipore, Eschborn, Germany) using an electroblotting chamber (Hoefer Scientific Instruments, Inc., San Francisco, CA) in 25 mM Tris, 192 mM glycine, 1% SDS, and 20% (v/v) methanol, at 200 mA for 16 h. All of the following steps were performed at 22°C. After blocking with 5% nonfat dried milk in PBS for 2 h, the membrane was incubated with TBS (0.5 mM Tris-HCl, 0.15 M NaCl, pH 7.4) and diluted with P-gp–specific antibody, monoclonal antibody C219 (1 μg/ml), or polyclonal antibody 909 (1500 dilution) for 2 h. After four washing steps (15 min each) with TBS containing 0.05% Tween 20 (TBS/T), the membrane was incubated for 2 h with anti-rabbit IgG and anti-mouse IgG, both with TBS containing 0.05% Tween 20 (TBS/T), the membrane was incubated for 2 h with anti-rabbit IgG and anti-mouse IgG, both with TBS containing 0.05% Tween 20 (TBS/T), the membrane was incubated for 2 h with anti-rabbit IgG and anti-mouse IgG, both with TBS containing 0.05% Tween 20 (TBS/T), the membrane was incubated for 2 h with anti-rabbit IgG and anti-mouse IgG, both with TBS containing 0.05% Tween 20 (TBS/T), the membrane was incubated for 2 h with anti-rabbit IgG and anti-mouse IgG, both with TBS containing 0.05% Tween 20 (TBS/T). 4 h. After washing four times in TBS/T, the membrane was incubated for 2 h with a primary antibody. The membrane was then washed four times with TBS/T, and incubated with a secondary antibody. The membrane was then washed four times with TBS/T, and incubated with a secondary antibody. The membrane was then washed four times with TBS/T, and incubated with a secondary antibody. The membrane was then washed four times with TBS/T, and incubated with a secondary antibody. The membrane was then washed four times with TBS/T, and incubated with a secondary antibody.

Results and Discussion

Solubilization of P-gp. The initial step in the analysis of the dexamethasone binding site was to solubilize, isolate, and purify the [3H]B9209-005–labeled P-gp from the cell membrane preparation of P-gp overexpressing CCRF-ADR5000 cells. Several detergents were examined for their efficiency of P-gp solubilization (Table 1). The solubilization was performed at a detergent concentration of 1% that is above the critical micelle concentration, and nonsolubilized membranes were separated by ultracentrifugation. To quantify the solubilization efficiency, P-gp was prelabeled with [3H]azidopine. The solubilized membranes were analyzed by SDS-PAGE and solubilized P-gp was determined by radioactivity quantification of the excised P-gp band. The solubilities are listed in Table 1 relative to the solubilization obtained with PAGE-sample buffer containing 2% SDS. The nonionic detergents n-octylglucoside and Triton X-100 showed only moderate solubilization efficiency, respectively, whereas the nonionic detergent Nonidet P-40 provided almost complete solubilization. Solubilization efficiencies for the zwitterionic detergents (deoxy-BIGCHAP, CHAPS, Zwittergent 3-12) were also moderate. However, the nonionic detergents deoxycholate and N-lauroylsarcosine showed complete solubili-
tion, respectively. Considering both the detergent exchange and the detergent removal, as well as compatibility with subsequent purification procedures, N-lauroylsarcosine was selected as detergent to solubilize P-gp. Further analysis of N-lauroylsarcosine showed that a minimum concentration of 10 to 20 mM was required for a complete solubilization of P-gp (Fig. 1). Therefore, the solubilization was performed in 20 mM N-lauroylsarcosine for all subsequent steps.

**Purification of [3H]B9209-005-Labeled P-gp.** For the purification of solubilized [3H]B9209-005-labeled P-gp, lectin affinity chromatography using RCA-120 was used. The Coomassie-stained gel after separation of the proteins from the eluate (lane 4) and the flow through (lane 3) of the RCA-120 chromatography is shown in Fig. 2a. These analyses were compared with those of the membrane proteins solubilized with either SDS-PAGE sample buffer (lane 1) or N-lauroylsarcosine (lane 2). The composition and intensity of the proteins in these two samples were identical, demonstrating complete solubilization with N-lauroylsarcosine. The protein composition of the flow-through (lane 3) seemed identical with that of the solubilized membranes (lane 2). The intensity of the protein bands from the flow-through, however, was lower because of the dilution from the chromatography. Gel electrophoresis of the eluate (lane 4) showed only a broad band at a molecular mass range of P-gp of 170 to 200 kDa where P-gp is expected. The radioactivity determination of the SDS-gel pieces indicated that the protein band at 170 kDa is [3H]B9209-005-labeled P-gp (Fig. 2b). This analysis also showed the presence of a second [3H]B9209-005-labeled protein at approximately 95 kDa.

For identification of the proteins, Western Blot analysis was carried out using monoclonal anti-P-gp antibody C219 (Fig. 2c) and polyclonal antibody 909 (Fig. 2d) raised against the synthetic peptide, P-gp(909–927). The P-gp protein band was detected by both antibodies in the solubilized membranes (lane 2, 3), in the flow-through (lane 3), and in the elution (lane 4). In addition, the monoclonal antibody C219 that showed antigenic affinity against the N- and C-terminal halves of P-gp (Kartner et al., 1985), detected the 95-kDa band as a P-gp-related protein. The 95-kDa protein was not detected by the polyclonal antibody 909 and was, therefore, assigned as an N-terminal proteolytic P-gp fragment (F1). However, F1 was found in the eluate by silver staining of the gel (data not shown). Another protein band at 55 kDa was detected in all samples except the elution fraction by both the monoclonal antibody C219 and the polyclonal antibody 909. Therefore, this protein was assigned as the corresponding C-terminal P-gp fragment. In order to obtain larger amounts of purified [3H]B9209-005–labeled P-gp and F1 from solubilized membrane preparations, RCA-120 chromatography was employed in a continuous flow system. The capacity and stability of the RCA-column was assessed by quantification of [3H]B9209-005–labeled P-gp in the different chromatographic steps (Fig. 2e). The radioactivity chromatogram of P-gp showed that the capacity limit of the RCA-120 chromatography was reached at 5 mg of solubilized membrane proteins applied to a 2-ml matrix volume. This corresponds to approximately 30 μg of P-gp based on the ratio of P-gp to total membrane protein estimated to about 0.6% by densitometric determination of the P-gp band after immunoprecipitation (Borchers et al., 1996). Recoveries of P-gp and F1 in the eluate were 32 and 48%, respectively, and decreased by a factor of 2 after each use of the column because of the low stability of the lectins. This is shown by detection of a 30-kDa lectin subunit after gel electrophoresis (Fig. 2a, front of lane 4). In a control experiment it was shown that the instability is at least partially caused by the presence of the detergent N-lauroylsarcosine (data not shown).

**Trypsin Digestion of Purified, [3H]B9209-005-Labeled P-gp.** The [3H]B9209-005–labeled, purified P-gp was digested with trypsin at different concentrations, and the digestion mixture analyzed by SDS-PAGE followed by liquid scintillation counting of the gel slices. In the presence of N-lauroylsarcosine, P-gp and F1 were completely resistant to trypsin digestion up to an enzyme to substrate (E/S) ratio of 1:10 (data not shown). For complete digestion of P-gp an E/S of 2:1 was required as shown in Fig. 3, three radioactive, labeled proteolytic fragments with molecular masses of approximately 80, 25, and 8 15 kDa were obtained. At a 10-fold higher enzyme concentration, the fragments of higher molec-

![Fig. 1. Solubilization of P-gp in relation to the concentration of the detergent N-lauroylsarcosine.](image-url)

**TABLE 1**

<table>
<thead>
<tr>
<th>Detergent</th>
<th>Solubilization Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n-Octylglucoside</td>
<td>12</td>
</tr>
<tr>
<td>Triton X-100</td>
<td>33</td>
</tr>
<tr>
<td>Nonidet P-40</td>
<td>92</td>
</tr>
<tr>
<td>Deoxy-BIGCHAP</td>
<td>6</td>
</tr>
<tr>
<td>Deoxycholate</td>
<td>47</td>
</tr>
<tr>
<td>N-Lauroylsarcosine</td>
<td>103</td>
</tr>
<tr>
<td>Zwittergent 3-12</td>
<td>17</td>
</tr>
<tr>
<td>CHAPS</td>
<td>3</td>
</tr>
</tbody>
</table>

* Standard deviation of the P-gp solubilization efficiency was approximately 5%.
Fig. 2. Purification of P-gp from CCRF-ADR5000 membranes by RCA120 lectin-chromatography. RCA-120 column (1.5 ml gel volume) was loaded with 3 ml solubilized (20 mM N-lauroylsarcosine) CCRF-ADR5000 membrane proteins after photoaffinity labeling with 1.4 μM [3H]B9209-005 and incubated for 2 h at 4°C. After washing with solubilization buffer the glycoproteins were eluted with 0.2 M methyl-β-D-galactopyranoside. a, Coomassie-staining of the SDS-gel: lane 1, 30 μg of membrane proteins solubilized with SDS-PAGE sample buffer; 2, 30 μg of membrane proteins solubilized with 60 μl of 20 mM N-lauroylsarcosine; 3, 60-μl column flow-through; 4, 200-μl elution; 5, molecular mass markers. b, radioactivity determination of SDS-PAGE–separated proteins in the elution. c, Western blot with monoclonal antibody C219. d, Western blot with polyclonal antibody 909. The SDS-gels were loaded with: 1, molecular mass markers; 2, 30-μg membrane proteins solubilized with SDS-sample buffer; 3, 30-μg membrane proteins solubilized with 60 μl of 20 mM N-lauroylsarcosine; 4, 60-μl column flow-through; and 5, 114-μl elution. The molecular mass markers on the PVDF-membrane were stained with Ponceau S. RCA-120 chromatography of 2-ml gel volume by in continuous flow (1 ml/min). 1, loading: 15 ml of solubilized (20 mM N-lauroylsarcosine) plasma membranes (7.5 mg) after photoaffinity labeling with 1.2 μM [3H]B9209-005; 2, washing: 10 ml of solubilization buffer (20 mM N-lauroylsarcosine); 3, elution: 0.2 M methyl-β-D-galactopyranoside in solubilization buffer. P-gp concentration in the fractions (0.5–1 ml) was determined by radioactivity determination of the excised P-gp band in the SDS-gel from the PAGE of the individual fractions.
ular mass were further digested concomitant with a decrease of the 8- to 15-kDa fragment containing 57% of the initial radioactivity of P-gp and F1. Furthermore, high E/S (20:1) led to increased tryptic auto-proteolytic peptides, which might interfere with the mass spectrometric analysis. Increasing the reaction time of the proteolysis while using less enzyme was also unsuccessful because of a progressive decrease of the P-gp recovery with time.

In contrast to the proteolysis in N-lauroylsarcosine, lower E/S ratios were sufficient to produce low-molecular-mass tryptic fragments using the detergents CHAPS (E/S = 10:1) and n-octylglucoside (E/S = 1:5). Furthermore, the detergent exchange of N-lauroylsarcosine against CHAPS and n-octylglucoside (performed by ultra-filtration) provided complete separation of the lectin subunit from P-gp and F1. The radiogram of the SDS-PAGE analysis of the peptide mixture obtained by digestion in n-octylglucoside showed a single peak corresponding to a [3H]B9209-005-bound polypeptide of 7 to 8 kDa (Fig. 4a) with a shoulder at ~5 kDa indicating an additional [3H]B9209-005-bound peptide. The proteolysis in CHAPS led to the formation of two [3H]B9209-005–bound peptides with molecular masses of approximately 15 and 8 kDa (Fig. 4b). However, because aggregation occurred in the presence of CHAPS as shown by a front peak in the stacking gel (Fig. 4b), the tryptic digestion in the following experiments was performed in n-octylglucoside.

HPLC Isolation of the [3H]B9209-005–bound Peptides. Because of the complexity of the mixture of tryptic peptides from P-gp (179 possible cleavage sites) and contamination with auto-proteolytic tryptic peptides isolation of [3H]B9209-005–bound peptides was necessary before mass spectrometric analysis. For the isolation of the [3H]B9209-

![Fig. 3. Gel electrophoretic analysis of the tryptic digestion of [3H]B9209-005–labeled, affinity-purified P-gp/F1 in N-lauroylsarcosine. Digestion was carried out for 2.5 h at 37°C with different amounts of trypsin. The separation of the proteolytic digestion mixture was performed by a 7.5 to 20% polyacrylamide gradient gel. a, RCA-120 chromatography; b, proteolysis with 10 μg trypsin/ml; c, proteolysis with 100 μg trypsin/ml.](image)
005–bound peptides, reversed-phase HPLC (C4) was performed with an isopropanol/acetonitrile mixture as the organic mobile phase. Control experiments showed that the photoinduced linkage between [3H]B9209-005 and P-gp was sufficiently stable under these HPLC conditions. Figure 5 shows the HPLC UV chromatogram of the tryptic digest of [3H]B9209-005–labeled P-gp and its radiogram, as well as the UV chromatogram of trypsin after autoproteolysis. The radiogram showed two signals, with a peak at longer retention time (Fig. 5a, signal 2) containing two [3H]B9209-005–bound peptides with molecular masses of 8 to 10 and 5 kDa as shown by SDS-PAGE analysis (data not shown). The SDS-PAGE analysis of signal 1 showed free [3H]B9209-005, indicating some instability of the [3H]B9209-005–bound peptides in signal 2 (data not shown). It is known that photoinduced ligand-peptide bonds of certain azido-photoaffinity ligands can dissociate under HPLC conditions (Salvucci et al., 1992). However, no peak at the retention time of signal 2 was detected in the UV chromatogram of the trypsin autoproteolysis products (Fig. 5c), indicating that this fraction did not contain autoproteolytic fragments.

Mass Spectrometric Characterization of the [3H]B9209-005–bound Peptides. To identify the tryptic [3H]B9209-005–bound peptides, the HPLC fractions corresponding to signal 2 were pooled and analyzed by MALDI mass spectrometry (MS). The MALDI-mass spectra revealed three intense ion signals at m/z 5230, 5734, and 7416 (Fig. 6). The same ions were obtained after incubation with 2-mercaptoethanol, indicating that these peptides do not correspond to disulfide-linked sequences (data not shown). For assignment, the masses of these ions were compared with the masses of the tryptic peptides calculated from the amino acid sequence with and without the incorporation of one dexniguldipine molecule providing a mass increment of 577 amu based on simple carbon bond insertion of the photoaffinity binding. At the MALDI mass determination accuracy (±0.1%), no single mass assignment was obtained (Table 2); however, the fragment at m/z 7416 provided a single candidate sequence containing a dexniguldipine moiety.

The combined Edman-MS sequencing method after coupling with phenylisothiocyanate was applied for further identification (Nielsen et al., 1990). In contrast to conventional Edman sequencing, the combined Edman-MS method analyzes the peptides remaining after successive cleavage of the N-terminal amino acids by mass spectrometry. Furthermore, useful information can be gained by mass spectrometric analysis of the PTC-adducts after the Edman coupling step which can reveal the maximum number of free amino groups (ε-amino groups of lysine residues) and free thiol groups (cysteine residues) in the peptide. MALDI-MS analysis of the PTC-adducts of the fractions corresponding to the HPLC-signal 2 showed ion signals at m/z 8137, m/z 6624 and m/z 5514 (Table 3). A control MALDI experiment of the reaction mixture in the absence of PITC showed no differences before and after the Edman coupling step (data not shown), indicating that the [3H]B9209-005-bound peptide was stable under these conditions.

Assignment of [3H]B9209-005–Bound Peptides. Assigning a mass increment of 577 amu per dexniguldipine and of 135 amu per PTC molecule, the molecular mass increase for the three ions at m/z 5230, 5734, and 7416 corresponds to incorporation of 5, 3, and 2 PTC-molecules, respectively. This means that the ion at m/z 7416 can only be assigned to a peptide containing at least four lysine residues, hence it can only be assigned to the [3H]B9209-005–bound P-gp peptide sequence, 468–527 (Table 3). The ion at m/z...
5734 was assigned to the tryptic P-gp peptide 620–670 because this peptide contains three lysine residues. The mass spectrometric analysis of the Edman coupling product of the ion at m/z 5230 could not be unambiguously assigned because the two possible peptides possess more than one lysine residue (Table 3). Nevertheless, this result does not preclude the assignments in Table 3, because the number of incorporated PITC groups is not necessarily the sum of N-terminal amino groups and all lysine residues. Thus, incomplete coupling of the amino groups with PITC has been shown for hen egg lysozyme and the disulfonated insulin B-chain (Nielsen et al., 1990). The MALDI mass spectra of samples obtained after Edman cleavage of PTC coupling products did not yield interpretable results because of low ion abundance and signal-to-noise ratios, and possible decomposition of dexniguldipine adducts.

Conclusions

In this study, we have identified the interacting binding site of the chemosensitizer dexniguldipine, a dihydropyridine derivative, in human P-gp using a combination of photoaffinity and mass spectrometric approaches. For photoaffinity labeling, the tritiated dexniguldipine analog [3H]B9209-005 was used, which has chemosensitizing potency identical to that of dexniguldipine and is, therefore, suitable for elucidation of the binding sites (Boer et al., 1996; Borchers et al., 1996). The mass spectrometric analysis localized the dexniguldipine binding site to the P-gp sequence 468–527, in agreement with previous immunoprecipitation experiments showing that the dexniguldipine binding site is in the N-terminal half of the protein P-gp (Borchers et al., 1996). This sequence region is flanked by the Walker motifs A and B of the N-terminal ATP-binding cassette.

The model of human P-gp based on hydropathy analysis (Gottesman and Pastan, 1988) suggests that the sequence region 468–527 is localized in the cytoplasm which is in agreement with previous binding analysis of dexniguldipine to membranes of CCRF-ADR5000 cells (Ferry et al., 1992). In addition, recent photoaffinity labeling competition studies with [3H]B9209-005 in whole cells and [3H]vinblastine binding analysis have shown that dexniguldipine blocks vinblastine binding, and thereby transport by P-gp, by acting at a domain accessible only from the cytoplasm (Ferry et al., 2000). However, the binding sequence identified is significantly different from the previously postulated major binding sites of chemomodulators and cytostatics in the transmembrane domains 5, 6 and 11, 12 and their connecting extracellular loops. These data were based mainly on immunological analysis of P-gp proteolytic fragments after photoaffinity labeling with [3H]azidopin (Bruggemann et al., 1989; 1992; Yoshimura et al., 1989), 125I-forskolin derivatives (Morris et al., 1994), and 125I-arylazidoprazosin (Greenberger et al., 1991). However, mutation studies have supported these results, suggesting that other regions may also play an important role in defining the drug-binding domain (Ambudkar et al., 1999). In more recent studies, further analytical approaches have been used to identify the photo-affinity labeled binding sites of cytostatics and chemosensitizers. Using Edman sequencing of radiolabeled peptides, the binding site of iodozymycin (the Bolton-Hunter derivative of the anthracycline daunomycin) was localized to amino acids (aa) 230 to 312 of hamster P-gp. This region, according to the hydrophobicity model of Gottesman and Pastan (1988), forms the distal part of TM4 (the second cytoplasmic loop) and the proximal part of TM5 (Demmer et al., 1997). Applying the same analytical approach, three binding sites of iodoarylazidoprazosin
were found in the regions of aa 248 to 312 (TM4 to TM5), aa 758 to 800 (beyond TM8), and aa 1160 to 1218, which are located within the second cytosolic NBD (Isenberg et al., 2001). Using overlapping peptide mapping with different chemical cleavage agents and immunoprecipitation, the binding site of cyclosporin A was localized to aa 953 to 1007, a region between the end of TM11 and the end of TM12 (Demeule et al., 1998). It is worth noting that cyclosporin A as well as viblastine bind with high affinity to the iodomycin binding site (see above) (Demmer et al., 1997). Using benzophenone analogs the binding domain of paclitaxel has been analyzed by photoaffinity labeling (Wu et al., 1998). It is important that the labeling of the drug binding site depends on the position of the benzophenone group in paclitaxel. All these results suggest that the drug binding domain is funnel-shaped, narrow at the cytoplasmic side (9–25 Å), and wider at the extracellular surface (Loo and Clarke, 2001). The different drug binding sites in our results may be explained by the different position of the photoactivatable group (azido group) in other ligands compared with [3H]B9209-005. In all these photoaffinity ligands, the azido group is located in the hydrophobic site chain, whereas the azido group in [3H]B9209-005 is directly in the pharmacophore, dihydropyridine moiety.

In a recently proposed structural model of P-gp (Jones and George, 1998), the dexniguldipine binding site corresponds to a region composed of two membrane-spanning β-strands (β-15 and β-16) followed by a cytosolic loop-helix (α-6) component (Fig. 7). If the dexniguldipine binding site is in a cytoplasm-localized P-gp region (Ferry et al., 1992), the binding site in this model can be assigned to the sequence 491–526, which includes the loop-(α-6)-helix component. The model suggests that this region is near the Walker A and B motifs of the N-terminal nucleotide binding site, indicating

**TABLE 2.** Assignment of ion signals determined by MALDI-MS analysis of the radioactive HPLC-fraction (signal 2 in Fig. 6) from the tryptic digestion of [3H]B9209-005-labeled P-gp/F1.

Photochemical incorporation of dexniguldipine leads to a mass increment of 577 amu. Molecular mass was calculated from the amino acid sequence.

<table>
<thead>
<tr>
<th>MALDI-MS</th>
<th>Dexniguldipine Incorporation</th>
<th>Tryptic P-gp Peptide</th>
<th>Lysine Residues</th>
<th>Molecular Mass (Theoretical)</th>
</tr>
</thead>
<tbody>
<tr>
<td>m/z</td>
<td>aa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7416</td>
<td>–</td>
<td>147–210</td>
<td>3</td>
<td>7417</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>443–502</td>
<td>1</td>
<td>7420</td>
</tr>
<tr>
<td>5734</td>
<td>–</td>
<td>465–527</td>
<td>4</td>
<td>7418</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>620–670</td>
<td>3</td>
<td>5735</td>
</tr>
<tr>
<td>5230</td>
<td>–</td>
<td>1015–1061</td>
<td>1</td>
<td>5734</td>
</tr>
<tr>
<td></td>
<td>+</td>
<td>620–666</td>
<td>3</td>
<td>5235</td>
</tr>
</tbody>
</table>

+, incorporation of dexniguldipine; −, no incorporation.

**TABLE 3.** MALDI-MS data of P-gp peptides (HPLC signal 2) after one Edman coupling step with phenylisothiocyanate

MALDI mass spectrometric analysis of the [3H]B9209-005-bound P-gp peptide (fraction of HPLC signal 2 in Fig. 6) after first Edman coupling procedure. For the Edman experiments of the TMs 4 to 6 and 10 to 12 suggest that the drug binding domain is funnel-shaped, narrow at the cytoplasmic side (9–25 Å), and wider at the extracellular surface (Loo and Clarke, 2001). The different drug binding sites in our results may be explained by the different position of the photoactivatable group (azido group) in other ligands compared with [3H]B9209-005. In all these photoaffinity ligands, the azido group is located in the hydrophobic site chain, whereas the azido group in [3H]B9209-005 is directly in the pharmacophore, dihydropyridine moiety.

![](https://atba6o.7e64e.1374/loc.png)

**Fig. 7.** Dexniguldipine-HCl binding sequence in the topological P-gp model according to Jones and George (1998). The N-terminal is suggested to consist of 16 transmembrane β-sheets (arrowed rectangles) and six cytoplasmic α-helices (rectangles). The lettered boxes A (Walker A motif), B (dodecapeptide), and C (Walker B motif) represent the ATP domains. The numbered residues are co-ordinate signposts for the topology. The dexniguldipine-HCl binding sequence 468–527 is highlighted in bold.
that the chemosensitizer binding site and ATP binding/utilization domains interact directly with each other.

It is well known that drug binding and ATP hydrolysis sites, as well as the chemosensitizer site and the ATP hydrolysis, are intimately coupled (Ramachandra et al., 1998). Kinetic studies using [3H]vinblastine binding competition analysis also elucidated that the binding of nucleotides to P-gp reduces availability of the drug binding sites (Martin et al., 2000). However, the mechanism of these interactions is not clearly understood. More detailed structure-function analyses at the molecular level are necessary to elucidate a three-dimensional structure of the interaction site, which should provide a better understanding of the mechanism of action of P-gp. A recent structural study using cryomicroscopy of two-dimensional crystals yielded an 10-A resolution structure of P-gp, which has shown that nucleotide binding causes a repacking of the transmembrane domains and a reduction of the drug binding affinity, thus confirming and explaining the results of kinetic studies (Rosenberg et al., 2001). As shown in this study, the combination of photoaffinity labeling and mass spectrometry is an efficient molecular approach to identify the binding sequences. Furthermore, most recent MS developments, such as tandem-MS and high-resolution Fourier transform MS techniques, have the potential to identify ligand-interacting amino acids precisely (Borchers et al., 1999; Fligge et al., 2000; Bauer et al., 2001; Kohlmann et al., 2002; Przybylski et al., 2002). Furthermore, photoaffinity labeling experiments using ligands with the photoactivable group at different positions allow the identification of the ligand-interacting amino acids in the binding area. Such data should provide constraints that can be used in computational chemistry to model the three-dimensional structure of the binding site which is essential for understanding the mechanism of P-gp and for the structure-based design of chemosensitizers.

Acknowledgments

We gratefully acknowledge the expert assistance of Stefan Witt Klaus Hägge with the HPLC and mass spectrometric analysis.

References


